Research Papers:
A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis
Metrics: PDF 2958 views | HTML 3069 views | ?
Abstract
Bing-yan Zhu1, Bo-yang Shang1, Yue Du1, Yi Li1, Liang Li1, Xian-dong Xu1, Yong-su Zhen1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Correspondence to:
Yong-su Zhen, email: [email protected]
Keywords: macropinocytosis, HDAC inhibitors, trans-cinnamic acid, neutral red
Received: September 27, 2016 Accepted: January 08, 2017 Published: January 18, 2017
ABSTRACT
Previous studies have shown that intensive macropinocytosis occurs in cancer cells and neutral red (NR) is noted for its capability to enter into the cell massively through a process mimetic to macropinocytosis. In addition, trans-cinnamic acid (tCA) has been found to be an inhibitor of histone deacetylase (HDAC). In the present study, cinnamoylphenazine (CA-PZ) that consists of NR and tCA moieties was synthesized and evaluated. As shown, CA-PZ massively entered into colon carcinoma HT-29 cells and pancreatic carcinoma MIA PaCa-2 cells and this entry was blocked by 5-(N-ethyl-N-isopropyl) amiloride (EIPA, an inhibitor of macropinocytosis), indicating a macropinocytosis-mediated uptake. Furthermore, CA-PZ markedly increased the protein expression levels of acetyl-H3, acetyl-H4 and p21 in HT-29 cells and MIA PaCa-2 cells. CA-PZ significantly inhibited the growth of colon carcinoma HT-29 and pancreatic carcinoma MIA PaCa-2 xenografts. By in vivo imaging, CA-PZ displayed prominent accumulation in the tumor xenografts. The study indicates that the newly synthesized CA-PZ acts as an HDAC inhibitor in association with intensive macropinocytosis-mediated intracellular delivery in cancer cells. The use of neutral red for preparation of chimeric molecules with the attribute of macropinocytosis-mediated intracellular delivery might open an alternative way for development of HDAC inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14714